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While breast cancer prognoses are generally good, different molecular subtypes are
known to have varying outcomes. Previous studies using breast cancer registries have
suggested that high parity may be an adverse prognostic factor in luminal breast cancer,
but breast cancer subtype definitions have varied and there have been few prospective
studies. We therefore collected prospective data from patients diagnosed with early
breast cancer at a single institution and followed them for a median of 8.5 years. All
patients (N = 594) were treated according to Finnish national guidelines using modern
treatment modalities in a Finnish university hospital. Clinicopathological surrogates of
the intrinsic breast cancer subtypes were updated to match European Society for
Medical Oncology 2015 Early Breast Cancer Clinical Practice Guidelines. The overall
10-year breast cancer–specific survival (BCSS) was 91.4%, with the longest 10-year
BCSS observed in luminal A-like cancers (97.9%) and the worst in luminal B-like (HER2
positive) cancers (80.6%). Parity of ≥ 5 deliveries was also associated with poor BCSS
(univariate P = 0.0020). However, when the subtypes were assessed separately in a
multivariate analysis that included tumor size and nodal status, high parity remained
significant only in luminal B-like (HER2 negative) cancers (HR = 2.63; 95% confidence
interval= 1.04–6.62; P= 0.040). Our results suggest excellent overall 10-year BCSS but
indicate that high parity is an adverse prognostic factor in luminal B-like (HER2 negative)
breast cancers.
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INTRODUCTION
Various gynecological and reproductive patient history factors have been associated with increased
breast cancer risks and prognoses (1, 2). Complex reproductive factors continue to be significant
determinants of breast cancer risk: breast cancer risks seems to be transiently higher during the
initial years after delivery, but are subsequently reduced for a prolonged period of time (3, 4). It
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has been suggested that the initial risk increase risk may be due
to hormonal stimuli leading to proinflammatory activation and
changes in tumor microenvironments (5, 6).
Previous findings have also suggested that pregnancy-
related effects on breast cancer incidence and prognoses
may vary among breast cancer subtypes (7–9). The five
intrinsic breast cancer subtypes, which are classed according
to their immunohistochemical (IHC) surrogates using the
European Society for Medical Oncology (ESMO) 2015 Early
Breast Cancer Clinical Practice Guidelines, differ in terms
of both their molecular constitutions and patient prognoses
(10–12). Although evidence about the prognostic role of
patient reproductive history is still emerging, it has become
clear that reproduction-related risk factors differ among the
breast cancer subtypes (13–15). In particular, registry- and
population-based studies have suggested that high parity is an
adverse prognostic factor in luminal subtypes and in triple-
negative breast cancer (TNBC); however, breast cancer subtype
definition has varied, and there have been few prospective
studies (7, 9, 13, 15, 16).
Moreover, although breast cancer survival and mortality
have been well studied (17, 18), there have been few
prospective studies that report on long-term breast cancer–
specific survival (BCSS) for each molecular subtype of breast
cancer using real-world data. The purpose of the present
study was therefore to evaluate subtype-specific long-term
outcomes and the importance of reproductive anamnesis as
potential prognostic factors in patients diagnosed with early
breast cancer.
MATERIALS AND METHODS
Prospective patient data were collected at Oulu University
Hospital in 2003–2013. All participants (N = 594) had been
diagnosed with early, invasive breast cancer and received
treatment at Oulu University Hospital (Table 1). Patients with
previous breast cancer diagnoses or distant metastases at the time
of diagnosis were excluded.
The assessments of these prognostic factors were determined
at time of the initial diagnosis in the accredited Oulu University
Hospital pathology laboratory as a part of routine diagnostics.
Based on this, tumors were classed into five intrinsic subtypes
according to ESMO Early Breast Cancer Clinical Practice
Guidelines (12). Luminal A-like carcinomas expressed both
estrogen receptors (ER) and progesterone receptors (PR), but
HER2 was not overexpressed and Ki-67 was expressed in <15%
of their cells. Luminal B-like (HER2 negative) carcinomas were
also ER positive and HER2 negative, but they either showed Ki-
67 expression in>15% of their cells or were PR negative. Luminal
B-like (HER2 positive) carcinomas still expressed ER, but they
also overexpressed HER2. TNBCs were defined as tumors with
no expression of ER, PR andHER2. HER2 positive (non-luminal)
cases overexpressed HER2 but did not express either ER or PR.
Table 2 details the subtypes present in our study cohort.
Histopathology was evaluated according to current WHO
classifications, and tumor stage was assessed according to
TABLE 1 | The distribution of patient characteristics.
Age at breast cancer onset
28–40 years 37 (6.2%)
41–74 years 511 (86.0%)
75–87 years 46 (7.7%)
Median 58 years
Age at menarche
10–12 years 159 (26.8%)
13–14 years 205 (34.5%)
15–17 years 97 (16.3%)
Missing 133 (22.4%)
Median 13 years
Menopausal status
Premenopausal 156 (26.3%)
Perimenopausal 10 (1.7%)
Postmenopausal 390 (65.7%)
Missing 38 (6.4%)
Median age at menopause 48 years
Number of deliveries before breast cancer diagnosis
0 67 (11.3%)
1 77 (13.0%)
2 186 (31.3%)
3 118 (19.9%)
4 45 (7.6%)
≥ 5 41 (6.9%)
Missing 60 (10.1%)
Median number of deliveries 2
TNM classifications (19). The expressions of ER, PR and Ki-
67 were assessed using the IHC methods previously described
(20). HER2 expression was then assessed using IHC and
chromogenic in situ hybridization (CISH) to confirm any positive
results. Any sample with a positive result of six or more
gene copies according to CISH was considered to be HER2
positive (21).
Statistical Analyses
Statistical analyses were performed using SPSS Statistics software
version 25.0 for Mac (IBM Corporation, Armonk, NY, USA).
Survival was analyzed using Kaplan-Meier curves and the
log-rank test. BCSS was calculated from the date of surgical
tumor removal to the time of breast cancer–related death.
Prognostic factors were reformatted as two-classed variables for
the analyses. The effect of parity in survival was assessed using
five deliveries as a cut-off point. Multivariate analyses were
conducted using Cox multivariate regression analyses (the co-
variates were tumor size and nodal status); tumor sizes were
assessed as either T1 or T2–4 and nodal status was categorized
as either N0 or N1–3. Crosstabulation was used to compare
the groups and two-sided Pearson’s Chi-square test or Fisher’s
exact test were used as applicable to determine significance.
Continuous variables were assessed using the Mann Whitney
U test or Pearson Correlation test. P-values < 0.05 were
considered significant.
Frontiers in Oncology | www.frontiersin.org 2 August 2020 | Volume 10 | Article 1470
Jääskeläinen et al. High Parity in Breast Cancer
TABLE 2 | The distribution of tumor characteristics.
T class
T1 384 (64.6%)
T2 189 (31.8%)
T3 19 (3.2%)
T4 2 (0.3%)
N class
N0 368 (62.0%)
N1 162 (27.3%)
N2 50 (8.4%)
N3 14 (2.4%)
Histopathology
Ductal 456 (76.8%)
Lobular 91 (15.3%)
Other 47 (7.9%)
Histopathological grade
Grade 1 103 (17.3%)
Grade 2 293 (49.3%)
Grade 3 172 (29.0%)
Unknown 26 (4.4%)
ER expression
Negative (0%) 92 (15.5%)
Weak (1–9%) 18 (3.0%)
Moderate (10–59%) 26 (4.4%)
High (> 59%) 455 (76.6%)
Unknown 3 (0.5%)
PR expression
Negative (0%) 146 (24.6%)
Weak (1–9%) 81 (13.6%)
Moderate (10–59%) 65 (10.9%)
High (> 59%) 298 (50.2%)
Unknown 4 (0.7%)
HER2 status
HER2 positive (CISH) 61 (10.3%)
HER2 negative 533 (89.7%)
Ki-67 expression
Negative (< 5%) 41 (6.9%)
Weak (5–14%) 268 (45.1%)
Moderate (15–30%) 141 (23.7%)
High (> 30%) 136 (22.9%)
Variable status or unknown 8 (1.4%)
Tumor type
Unifocal 472 (79.5%)
Multifocal 122 (20.5%)
Breast cancer subtypes
Luminal A-like 271 (45.6%)
Luminal B-like (HER2 negative) 192 (32.3%)
Luminal B-like (HER2 positive) 33 (5.6%)
HER2 positive, non-luminal 27 (4.5%)
Triple negative 63 (10.6%)
Unknown 8 (1.4%)
Subtype division in patients with five or more deliveries
Luminal A-like 17 (41.5%)
Luminal B-like (HER2 negative) 16 (39.0%)
Luminal B-like (HER2 positive) 2 (4.9%)
HER2 positive, non-luminal 0
Triple negative 5 (12.2%)
Unknown 1 (2.4%)
ER, estrogen receptor; PR, progesterone receptor.
TABLE 3 | The distribution of adjuvant chemotherapy, radiotherapy, and
endocrine therapy.
Adjuvant chemotherapy
Anthracycline-based + taxane 129 (21.8%)
Anthracycline-based 130 (21.9%)
Other chemotherapy 25 (4.2%)
Trastuzumab + chemotherapy 61 (10.3%)
No adjuvant chemotherapy 247 (41.6%)
Missing 2 (0.3%)
Adjuvant radiation therapy
Yes 514 (86.5%)
No 80 (13.5%)
The first prescribed adjuvant endocrine therapy
Tamoxifen 164 (27.6%)
Aromatase inhibitor 222 (37.4%)
Tamoxifen + goserelin 2 (0.3%)
Other endocrine therapy 3 (0.5%)
No endocrine therapy 200 (33.7%)
Missing 3 (0.5%)
RESULTS
Clinical Characteristics
Median follow-up time was 102 months (range 2–186). During
follow-up, 34 patients (5.7%) were diagnosed with local relapse
and 60 patients (10.1%) were diagnosed with distant metastases.
The most frequent single site of metastasis was in the bones (17
patients, 2.9%), but multiple-site metastasis was most frequent
(24 patients, 4.0%). 88 (14.8%) of the patients had ER- and
PR- phenotype in their tumors, 58 (9.8%) had ER+ and
PR-, 4 (0.7%) ER– and PR + and 444 (74.7%) phenotype,
respectively. Altogether 347 (58.4%) of the patients received
adjuvant chemotherapy (Table 3). The frequency of adjuvant
chemotherapy was the lowest within the patients with luminal
A subtype (97 patients, 35.8%). 130 (67.7%) of the luminal B-
like (HER2 negative) patients received adjuvant chemotherapy
and the frequency was even higher with the patients with
HER2 overexpression subtype (27 patients, 100%), luminal B-like
(HER2 positive) subtype (30 patients, 90.9%) and triple-negative
subtype (57 patients, 90.5%). Subtype distribution (Table 2)
varied among the age groups. In patients ≤ 40 years, the most
frequent subtype was TNBC, while in both of the older age groups
(41–74 and ≥ 75), the most frequent subtype was the luminal A-
like subtype (Table 4). Parity was recorded at the initial time of
the early breast cancer diagnosis. Although the median number
was 2 (range 0–12), 41 patients had ≥ 5 deliveries. The highest
percentage of nulliparous women (18.5%) was observed among
patients with HER2 positive (non-luminal) breast cancer. These
results are presented in detail in Table 1.
Survival and Parity
Having ≥5 deliveries was the optimal cut-off as the predictor
of BCSS. Overall, having ≥5 deliveries was associated with a
poor BCSS (P = 0.0020) in univariate analyses; however, this
result was not confirmed in multivariate analyses (Figure 1).
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TABLE 4 | Subtype distribution for each age group.
Breast cancer subtypes according to age 594 (100%)
28–40 years 37 (6.2%)
Luminal A-like 9 (24.3%)
Luminal B-like (HER2 negative) 11 (29.7%)
Luminal B-like (HER2 positive) 1 (2.7 %)
HER2 positive, non-luminal 3 (8.1%)
Triple negative 13 (35.1%)
Unknown 0
41–74 years 511 (86.0%)
Luminal A-like 238 (46.6%)
Luminal B-like (HER2 negative) 168 (32.9%)
Luminal B-like (HER2 positive) 30 (5.9%)
HER2 positive, non-luminal 24 (4.7%)
Triple negative 45 (8.8%)
Not fitting any subtype 1 (0.2%)
Unknown 5 (1.0%)
When the subtypes were assessed separately high parity was
significantly correlated with poor BCSS only in luminal B-like
(HER2 negative) cancers (log-rank P = 0.00074). This was
determined using a multivariate analysis (HR = 2.63; 95% CI =
1.04–6.62; P = 0.040) that included tumor size (T1 vs. T2–4; HR
= 2.98; 95% CI = 1.27–6.99; P = 0.012) and nodal status (N0 vs.
N1–3; HR = 5.21; 95% CI = 1.70–16.0; P = 0.0039) (Table 5).
When age at breast cancer onset (a continuous variable) was
included to the Cox regression model along with parity, having
≥5 deliveries was still an independent prognostic factor with the
HR of 3.45 (95% CI 1.62–7.38; P = 0.001), while age was not
significant with the HR of 0.98 (95% CI 0.96–1.01; P = 0.22).
There was no difference in BCSS when parous and nulliparous
women were compared (P = 0.991).
Associations Between Deliveries and
Clinicopathological Characteristics
High parity (≥5 deliveries) before an initial breast cancer
diagnosis was associated with the presence lymph node
metastases in a whole-cohort analysis (P = 0.0020), but not
when the subtypes were assessed separately. Overall, 24.4% of
patients with ≥ 5 deliveries had a distant recurrence during the
follow-up period, in comparison to 9.91% in the group with
≤ 4 deliveries (P = 0.0090). The number of deliveries did not
associate with T-class, grade, Ki-67 expression, subtype, HER2,
ER or PR expression or the presence of bilateral or multifocal
breast cancer. The absolute number of deliveries correlated with
the age of breast cancer onset (P = 0.000078; correlation co-
efficient 0.170).
Survival and Subtypes
Overall, the estimated 5- and 10-year BCSS were 95.8 and 91.4%,
respectively (Table 6). The longest estimated 5- and 10-year
BCSS were observed in luminal A-like cancers (99.6 and 97.9%,
respectively), while the worst 5-year BCSS was observed in the
TNBC subgroup (85.6%) and the worst 10-year BCSS was seen in
the luminal B-like (HER2 positive) subgroup (80.6%). When the
subtypes’ BCSS were compared, the luminal A-like subtype had
a more favorable outcome than any other subgroup (P < 0.005
for all). We did not observe any other statistically significant
differences in BCSS between the subgroups.
DISCUSSION
We collected and analyzed prospective data from 594 patients
with invasive early breast cancer. Using IHC surrogates, the
tumors were divided into five molecular subtype groups
according to the ESMO Early Breast Cancer Clinical Practice
Guidelines. Notably, we observed that high parity (≥5 deliveries)
predicted poor BCSS but only in luminal B-like (HER2 negative)
subtype tumors.
Previous studies have suggested that parity is correlated with
either favorable or unfavorable breast cancer prognoses (2, 15,
16). In particular, high parity has been associated with poor
outcomes for TNBC and luminal subtype tumors (7, 9, 13).
The discrepancies between studies may be due to heterogenous
patient material, varying subtype definitions or the dependence
on retrospective registry-based studies. There has been a lack
of prospective research of parity as an independent prognostic
factor using modern definitions of the intrinsic subtypes. To the
best of our knowledge, the present research is the first single-
institution study to use real-world prospective patient data to
assess parity as a BCSS prognostic factor.
We used widely recognized ESMO 2015 guidelines for
subtyping our breast cancer cases. Thus, five subtypes, based on
their ER, PR, Ki-67, and HER2 expression were used: luminal
A-like, luminal B-like (HER2 negative), luminal B-like (HER2
positive), TNBC and HER2 positive (non-luminal).
It has been previously reported that parity is differentially
associated with breast cancer subtypes—in particular, that
parous women are more likely to have TNBC than luminal
A breast cancers (22). However, we found that high parity
was prognostic of poor outcomes, when tumor size and nodal
status were controlled for, but only in luminal B-like (HER2
negative) subtype cancers. This suggests that parity may have
biological effects that extend to later diagnoses of breast cancer
and its metastasis, particularly in estrogen-dependent, rapidly
proliferating breast cancers. On the other hand, it seems that
having four or less deliveries is not sufficient to induce such
changes. Although it is always difficult to assess causality in
a cohort setting, this observed link between higher parity and
worse BCSS fulfills most of Bradford Hill’s classic causation
criteria (23).
Luminal B-like breast cancer subtypes are associated with
greater tumor aggressiveness and with significantly worse
prognoses than the luminal A-like subtypes (24–26). Despite
their positive ER expression, luminal B-like tumors may utilize
alternative pathways for growth, since they do not show an
equivalent expression of estrogen-regulated genes (24). It has
been suggested that ER expression plays an essential role in
parity-related changes, since the hormonal milieu of pregnancy
changes the mammary microenvironment, thus potentially
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FIGURE 1 | High parity (≥5 deliveries) before breast cancer diagnosis predicted poor breast cancer-specific survival in the overall cohort (A) and separately in luminal
B-like (HER2 negative) breast cancers (B). (C) Shows the long-term breast cancer-specific survival according to the intrinsic subtype immunohistochemical
surrogates. TNBC, triple-negative breast cancer.
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TABLE 5 | 5- and 10-year breast cancer–specific survival (BCSS).
Subtype 5-year BCSS 10-year BCSS
Luminal A-like 99.6% 97.9%
HER2 overexpression 92.4% 88.6%
Luminal B-like (HER2 negative) 95.7% 86.3%
TNBC 85.6% 83.9%
Luminal B-like (HER2 positive) 89.5% 80.6%
Whole cohort 95.8% 91.4%
TABLE 6 | Having five or more deliveries at the time of breast cancer diagnosis is
indicator of poor prognosis in multivariate analysis.
95% confidence interval p-value
Hazard ratio Lower Upper
≥ 5 deliveries 2.628 1.043 6.620 0.040
T2-4 2.983 1.273 6.993 0.012
N1-3 5.208 1.696 15.989 0.0039
stimulating growth (27). It has also been speculated that
pregnancy may significantly affect ER positive tumor progression
(28). It is plausible that the known alternative pathways for
growth, such as the epidermal growth factor receptor and
PI3K/AKT/mTOR pathways, are responsible for the association
between poor prognoses and high parity in luminal B-like (HER2
negative) subtype breast cancers (26).
The hypothesis of postpartum mammary gland involution
suggests that changes in the extracellular matrix occur
due to activation of collagen remodeling and fibrillar
collagen disposition (5, 29). The post-pregnancy mammary
microenvironment may thus become cancer-promoting by
inducing metastasis through the collagen, COX2 and wound-
healing pathways (5, 6). In addition, these metastasis-promoting
changes in the breast may be present for only a certain period
of time, since only breast cancer diagnoses within 10 years
of last childbirth have been shown to be an independent
prognostic factor for distant metastasis (30). Moreover, the
subtype-specific changes in the extracellular matrix may be
related to the relationship between high parity and luminal
B-like (HER2 negative) tumors’ prognoses. For instance,
Bergamaschi et al. (31) studied extracellular matrix gene profiles
in breast cancer and were able to divide patients into different
prognostic groups based on their tumors’ gene expressions.
Furthermore, histologically defined breast cancer subtypes
were not equally present among the gene expression groups,
potentially suggesting that the extracellular matrix differed
between subtypes. However, the histological subtypes used by
Bergamaschi et al. differed from those used in the present study
and are thus not directly comparable.
Overall, we observed excellent long-term outcomes in our
prospective cohort, with a 10-year BCSS of 91.4%. The best
BCSS was among patients with luminal A-like subtype tumors,
among whom only 2.1% died due to breast cancer in our 10-
year Kaplan-Meier estimate. This is consistent with results from
a population-based study utilizing molecular subtype divisions
that found that luminal A-like subtypes were associated with the
lowest 10-year all-cause mortality of all tumor subtypes, while the
HER2-enriched subtype had the highest (18). Similarly, Hennigs
et al. (17) recently reported on a large prospective single-center
study assessing the 5-year outcomes of non-metastatic breast
cancer patients; they found that patients with luminal A-like
subtype (IHC surrogate) tumors had the best prognoses in terms
of overall survival (OS), disease-free survival, distant disease-free
survival and relative OS. Furthermore, although they assessed
patients during a notably shorter follow-up period than we did,
they reported 5-year relative OS (BCSS not reported) in the whole
cohort to be 94.7%; this is similar to our present finding that 5-
year BCSS was 95.8%. Likewise, another retrospective study by
Deniz et al. (32) found that luminal A-like subtype cancers had
the most favorable outcomes; they observed 5-year BCSS to be
96.5%, compared to our present finding of 99.6%. In addition,
both Hennigs et al. and Deniz et al. found that the TNBC subtype
had the least favorable 5-year prognoses (OS 78.5% and BCSS
87.6%, respectively) (17, 32). This is consistent with our finding
that TNBC subtypes had the worst 5-year prognosis, with a BCSS
of 85.6%. Interestingly, however, we found that luminal B-like
(HER2 positive) subtype tumors had the worst 10-year BCSS,
at 80.6%, while TNBC-subtype tumors had a 10-year of BCSS
of 83.9%. However, in all these studies, as well as in the present
research, luminal A-like subtype tumors were themost frequently
diagnosed (17, 18, 32).
The present study has some limitations. First, we defined
the molecular subtypes using IHC molecular subtype surrogates
instead of gene expression profiling, potentially leading to
some inaccuracies in the data, since IHC relies on a more
subjective assessment than gene expression profiling. However,
all of our IHC procedures have been validated, thereby reducing
this concern. Second, another limitation is that we were
unable to gather information on some potentially confounding
reproductive factors, such as age at first birth, breastfeeding
history, time between last birth and breast cancer onset, and
use of oral contraceptives and hormone replacement therapy
(15, 33–35). Thirdly, the number of patients and especially the
number of breast cancer-related deaths in the patients with
luminal B-like (HER2 negative) cancer was rather low, 25. These
results should be therefore evaluated cautiously and need to be
confirmed in a larger material. Nonetheless, our study has a
number of strengths, including its modern definition of breast
cancer subtypes according to the ESMO Early Breast Cancer
Clinical Practice Guidelines, its assessment of subtype-specific
BCSS, its median follow-up time of 8.5 years and its use of
contemporary treatment modalities and modern diagnostics in
a university hospital. In addition, all of our patient data were
reliably collected and stored.
In conclusion, ≥5 deliveries before breast cancer diagnosis
predicted poor BCSS but interestingly only in luminal B-
like (HER2 negative) subtype tumors. Although we observed
excellent overall long-term breast cancer–specific outcomes,
there was an absolute difference of 17.3% between the 10-year
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BCSS of the subtype with the best prognosis (luminal A-
like) and the subtype with the worst prognosis (luminal B-
like HER2 positive). These subtype-specific 10-year BCSS results
provide essential additional data about long-term outcomes
using modern treatment modalities. However, further research
is needed to establish the prognostic associations between parity
and individual molecular breast cancer subtypes.
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